Ironwood Pharmaceuticals starts phase III program for IW-3718 in persistent gastroesophageal reflux disease

This article was originally published here

Ironwood Pharmaceuticals has initiated two Phase III clinical trials to assess the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply